These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 24803665)

  • 1. Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
    Kiel C; Serrano L
    Mol Syst Biol; 2014 May; 10(5):727. PubMed ID: 24803665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
    Tidyman WE; Rauen KA
    Curr Opin Genet Dev; 2009 Jun; 19(3):230-6. PubMed ID: 19467855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mosaic RASopathies.
    Hafner C; Groesser L
    Cell Cycle; 2013 Jan; 12(1):43-50. PubMed ID: 23255105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort.
    Chen H; Li X; Liu X; Wang J; Zhang Z; Wu J; Huang M; Guo Y; Li F; Wang X; Fu L
    Orphanet J Rare Dis; 2019 Feb; 14(1):29. PubMed ID: 30732632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins.
    Montero-Bullón JF; González-Velasco Ó; Isidoro-García M; Lacal J
    Orphanet J Rare Dis; 2021 Jul; 16(1):303. PubMed ID: 34229750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASopathy Gene Mutations in Melanoma.
    Halaban R; Krauthammer M
    J Invest Dermatol; 2016 Sep; 136(9):1755-1759. PubMed ID: 27236105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
    Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
    Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
    Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
    Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.
    Rauen KA; Tidyman WE
    Dis Model Mech; 2024 Jun; 17(6):. PubMed ID: 38847227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.
    Gripp KW; Aldinger KA; Bennett JT; Baker L; Tusi J; Powell-Hamilton N; Stabley D; Sol-Church K; Timms AE; Dobyns WB
    Am J Med Genet A; 2016 Sep; 170(9):2237-47. PubMed ID: 27264673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
    Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
    Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining RASopathy.
    Rauen KA
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35103797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
    Gripp KW; Schill L; Schoyer L; Stronach B; Bennett AM; Blaser S; Brown A; Burdine R; Burkitt-Wright E; Castel P; Darilek S; Dias A; Dyer T; Ellis M; Erickson G; Gelb BD; Green T; Gross A; Ho A; Holder JL; Inoue SI; Jelin AC; Kennedy A; Klein R; Kontaridis MI; Magoulas P; McConnell DB; McCormick F; Neel BG; Prada CE; Rauen KA; Roberts A; Rodriguez-Viciana P; Rosen N; Rumbaugh G; Sablina A; Solman M; Tartaglia M; Thomas A; Timmer WC; Venkatachalam K; Walsh KS; Wolters PL; Yi JS; Zenker M; Ratner N
    Am J Med Genet A; 2020 Mar; 182(3):597-606. PubMed ID: 31825160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RASopathies.
    Rauen KA
    Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS signalling in energy metabolism and rare human diseases.
    Dard L; Bellance N; Lacombe D; Rossignol R
    Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number variants including RAS pathway genes-How much RASopathy is in the phenotype?
    Lissewski C; Kant SG; Stark Z; Schanze I; Zenker M
    Am J Med Genet A; 2015 Nov; 167A(11):2685-90. PubMed ID: 25974318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
    Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
    Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMR-based functional profiling of RASopathies and oncogenic RAS mutations.
    Smith MJ; Neel BG; Ikura M
    Proc Natl Acad Sci U S A; 2013 Mar; 110(12):4574-9. PubMed ID: 23487764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undiagnosed RASopathies in infertile men.
    Juchnewitsch AG; Pomm K; Dutta A; Tamp E; Valkna A; Lillepea K; Mahyari E; Tjagur S; Belova G; Kübarsepp V; Castillo-Madeen H; Riera-Escamilla A; Põlluaas L; Nagirnaja L; Poolamets O; Vihljajev V; Sütt M; Versbraegen N; Papadimitriou S; McLachlan RI; Jarvi KA; Schlegel PN; Tennisberg S; Korrovits P; Vigh-Conrad K; O'Bryan MK; Aston KI; Lenaerts T; Conrad DF; Kasak L; Punab M; Laan M
    Front Endocrinol (Lausanne); 2024; 15():1312357. PubMed ID: 38654924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
    Tajan M; Paccoud R; Branka S; Edouard T; Yart A
    Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.